Trial Profile
A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Mar 2009
Price :
$35
*
At a glance
- Drugs Trandolapril (Primary) ; Verapamil (Primary) ; Verapamil/trandolapril (Primary)
- Indications Diabetic nephropathies; Hypertension
- Focus Therapeutic Use
- Acronyms BENEDICT
- Sponsors Abbott Laboratories
- 07 Aug 2008 New trial record.